{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:10:16Z","timestamp":1788952216567,"version":"build-2803163510"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary membranous nephropathy (PMN) and minimal change disease (MCD) are common causes of nephrotic syndrome in adults and represent the two diseases in which anti-CD20 monoclonal antibodies are most widely used. Previous studies have demonstrated that the clinical efficacy of rituximab (RTX) is influenced by the baseline level of proteinuria. Obinutuzumab is a novel anti-CD20 monoclonal antibody with superior efficacy and safety to RTX. However, whether its therapeutic efficacy in PMN and MCD is similarly influenced by baseline proteinuria remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We recruited 40 patients with PMN and 42 patients with MCD confirmed by renal biopsy. All patients received obinutuzumab. All patients with PMN were divided into two groups based on baseline proteinuria: \u22648\u00a0g\/d group and &amp;gt;8\u00a0g\/d group. MCD patients were divided into two groups: the GC + obinutuzumab group and the Obinutuzumab group. Compared the clinical outcomes and side-effects of patients in different groups after a 12-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among patients with PMN and MCD, no statistically significant differences were observed between the two groups in complete remission (CR) rates, partial remission (PR) rates, or composite remission rates at the first, third, sixth, ninth, and 12th months. Kaplan-Meier analysis showed that there is no significant difference in cumulative CR rates and composite remission rates between two groups in patients with PMN and patients with MCD. At the end of follow-up, all patients exhibited a significant reduction in proteinuria, an increase in serum albumin, and no deterioration in kidney function. Furthermore, the safety profile of obinutuzumab was favorable in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that the efficacy of obinutuzumab in PMN and MCD is not affected by the baseline level of proteinuria. Besides, obinutuzumab monotherapy has shown satisfactory therapeutic effects in both PMN and MCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1912188","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:16:37Z","timestamp":1788948997000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Does baseline proteinuria affect the efficacy of obinutuzumab in patients with primary membranous nephropathy and minimal change disease? a single-center retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xueting","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Nanchang University","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Nanchang University","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Nanchang University","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/ndt\/gfab323","article-title":"Proteinuria selectivity index predicts response to rituximab in adults with minimal change disease and focal segmental glomerulosclerosis","volume":"37","author":"Allinovi","year":"2022","journal-title":"Nephrology, dialysis, transplantation official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"B2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ndt\/gfaf127","article-title":"Urinary rituximab loss and rate of treatment failure in membranous nephropathy","volume":"41","author":"Allinovi","year":"2025","journal-title":"Nephrology, dialysis, transplantation official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/j.ekir.2025.06.019","article-title":"Obinutuzumab in rituximab-resistant podocytopathies: a single-center experience","volume":"10","author":"Angeletti","year":"2025","journal-title":"Kidney international reports"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"The New England journal of medicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrology, dialysis, transplantation official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"B6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clinical journal of the American Society of Nephrology CJASN"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","article-title":"Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children","volume":"18","author":"Dossier","year":"2023","journal-title":"Clinical journal of the American Society of Nephrology CJASN"},{"key":"B8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.akdh.2024.02.002","article-title":"Minimal change disease","volume":"31","author":"Gomez","year":"2024","journal-title":"Advances in kidney disease and health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/nejmoa2314471","article-title":"Autoantibodies targeting Nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"The New England journal of medicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Molecular cancer therapeutics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Annals of internal medicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000541972","article-title":"Obinutuzumab may be an effective and safe option for adult minimal change disease and focal segmental glomerulosclerosis patients after multitarget therapy including rituximab","volume":"56","author":"Lin","year":"2025","journal-title":"American journal of nephrology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"gfag104","DOI":"10.1093\/ndt\/gfag104","article-title":"Anti-Obinutuzumab antibodies in primary membranous nephropathy","volume":"19","author":"Liu","year":"2026","journal-title":"Nephrol. Dial. Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23755","DOI":"10.1038\/s41598-024-75281-9","article-title":"Clinical relevance of proteinuria selectivity index and fractional excretion of sodium in patients with nephrotic syndrome","volume":"14","author":"Nakayama","year":"2024","journal-title":"Scientific reports"},{"key":"B14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1681\/ASN.0000000642","article-title":"Anti-slit antibodies against Podocin and Kirrel1 in pediatric and adult podocytopathies","volume":"36","author":"Raglianti","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/asn.2021060794","article-title":"Discovery of autoantibodies targeting Nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"Journal of the American Society of Nephrology JASN"},{"key":"B17","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/ndt\/gfae230","article-title":"Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy","volume":"40","author":"Xu","year":"2025","journal-title":"Nephrology, dialysis, transplantation official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1778113","DOI":"10.3389\/fphar.2026.1778113","article-title":"Pharmacokinetic profiling of rituximab in glomerular diseases: key determinants and implications for personalized therapy","volume":"17","author":"Zhang","year":"2026","journal-title":"Frontiers in pharmacology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1912188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:16:38Z","timestamp":1788948998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1912188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":18,"alternative-id":["10.3389\/fphar.2026.1912188"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1912188","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1912188"}}